To further evaluate S1P and AAV-YAPdeltaC as a candidate therapeutic strategy in human AD, we employed human iPSCs-derived neurons carrying heterozygous or homozygous AD mutations (APP KM670/671NL) introduced by genome editing (Fig. 10a). Here, MBTPS1 is linked to Alzheimer disease.